Teva Locks In Tourette’s Frontrunner With $700m Emalex Buy Scrip Pharma Intelligence 15:12 Thu, 30 Apr
Teva signs off $900m Emalex buyout amid strategic pipeline boosting ploy Pharmaceutical Technology 11:27 Thu, 30 Apr
Teva Lowers 2026 Non-GAAP Operating Profit Outlook On Emalex Deal; On Track To Achieve 2027 Targets RTT News 13:19 Wed, 29 Apr
Emalex Receives U.S. Patent for Orally Disintegrating Ecopipam Formulation Business Wire (Press Release) 16:06 Thu, 09 Apr
